[PAR] [TLE] Novo Nordisk [SEP] Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.  Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (75%) of its voting shares. [PAR] [TLE] Liraglutide [SEP] Liraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.  Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes.  In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.
[PAR] [TLE] Novo Nordisk [ SEP ] Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd , Denmark , with production facilities in eight countries , and affiliates or offices in 75 countries . Novo Nordisk is controlled by majority shareholder Novo Holdings A / S which holds approximately 25 % of its shares and a supermajority ( 75 % ) of its voting shares . [PAR] [TLE] Liraglutide [ SEP ] Liraglutide ( NN2211 ) is a derivative of human incretin ( metabolic hormone ) glucagon - like peptide-1 ( GLP-1 ) that is used as a long - acting glucagon - like peptide-1 receptor agonist , binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion . Marketed under the brand name Victoza , it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes . In 2015 , Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight - related comorbid condition .
What is the brand name of the injectable drug for type 2 diabetes that was marketed by a Danish multinational pharmaceutical company with a majority shareholder Novo Holdings A/S?
What is the brand name of the injectable drug for type 2 diabetes that was marketed by a Danish multinational pharmaceutical company with a majority shareholder Novo Holdings A / S ?
Victoza
Victoza